Bardoxolone methyl
As of the edition of 20 October 2026, Bardoxolone methyl is a small molecule: stopped in 2023; acts on IKBKB, KEAP1 and NFE2L2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 33, 15 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Nutrition and metabolism; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 4 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Bardoxolone methyl.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Bardoxolone methyl.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 13 | 9 | 0 | 4 |
| Phase 2 | 13 | 8 | 0 | 5 |
| Phase 3 | 7 | 1 | 0 | 6 |
| All trials | 33 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biogen | Lead sponsor of trials | 2006 to now |
| Kyowa Kirin | Lead sponsor of trials | 2012 to now |